Aspira women's health receives final crosswalk pricing determination from the centers for medicare & medicaid services (cms)

Cms approves ovawatch sm 2024 price at $897 per test austin, texas, nov. 27, 2023 (globe newswire) -- aspira women's health inc. (“aspira” or “the company”) (nasdaq: awh), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that during the 2024 clinical laboratory fee schedule (clfs) rate setting process, the centers for medicare & medicaid services (cms) has approved the crosswalk of the fee to be paid to the company for ovawatch to the fee paid historically for ova1. aspira will be reimbursed at a rate of $897 for all ovawatch and ova1 tests processed for medicare patients meeting applicable coverage requirements beginning on january 1, 2024.
AWH Ratings Summary
AWH Quant Ranking